Infinity Pharmaceuticals, Inc. (INFI) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.28 k

Shareholding (Dec 2023)

FII

5.98%

Held by 31 FIIs

DII

80.57%

Held by 17 DIIs

Promoter

0.10%

Who are in the management team of Infinity Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Infinity Pharmaceuticals, Inc. includes Ms. Adelene Perkins as Chairman and CEO, along with Board members Mr. Norman Selby, Dr. Samuel Agresta, and independent directors Mr. David Beier, Dr. Anthony Evnin, and Dr. Richard Gaynor.

Is Infinity Pharmaceuticals, Inc. overvalued or undervalued?

20-Sep-2025

As of July 8, 2024, Infinity Pharmaceuticals, Inc. is considered overvalued and has deteriorated from a risky to a non-qualifying investment grade, with negative EV to EBIT and EV to EBITDA ratios, and significant underperformance compared to the S&P 500.

Is Infinity Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of November 29, 2024, Infinity Pharmaceuticals, Inc. shows a mildly bearish trend with daily moving averages indicating weakness, while it has significantly underperformed the S&P 500 over the past decade with a return of -99.99% compared to the S&P's 231.64%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.82

Return on Equity

109.47%

Price to Book

0.00

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Jun 2023)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-100.0%

6 Months

0.0%

1 Year

0.0%

2 Years

-100.0%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Infinity Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-15.60%

EBIT Growth (5y)

-6.70%

EBIT to Interest (avg)

-30.15

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.82

Sales to Capital Employed (avg)

0.07

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

35.81%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

-0.73

EV to EBITDA

-0.74

EV to Capital Employed

-4.59

EV to Sales

11.96

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

109.47%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 25 Schemes (13.35%)

Foreign Institutions

Held by 31 Foreign Institutions (5.98%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is -14.29% vs 40.00% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2023 is 9.09% vs -19.57% in Mar 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.60",
          "val2": "0.70",
          "chgp": "-14.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.00",
          "val2": "-11.40",
          "chgp": "12.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.00",
          "val2": "-11.00",
          "chgp": "9.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-17,358.50%",
          "val2": "-15,741.50%",
          "chgp": "-161.70%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 36.84% vs 11.76% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 1.99% vs -11.85% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.60",
          "val2": "1.90",
          "chgp": "36.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-44.40",
          "val2": "-44.60",
          "chgp": "0.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.40",
          "val2": "-45.30",
          "chgp": "1.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-17,294.30%",
          "val2": "-24,264.30%",
          "chgp": "697.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ

Jun'23

Mar'23

Change(%)

Net Sales

0.60

0.70

-14.29%

Operating Profit (PBDIT) excl Other Income

-10.00

-11.40

12.28%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-10.00

-11.00

9.09%

Operating Profit Margin (Excl OI)

-17,358.50%

-15,741.50%

-161.70%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2023 is -14.29% vs 40.00% in Mar 2023

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2023 is 9.09% vs -19.57% in Mar 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

2.60

1.90

36.84%

Operating Profit (PBDIT) excl Other Income

-44.40

-44.60

0.45%

Interest

0.20

Exceptional Items

0.00

Consolidate Net Profit

-44.40

-45.30

1.99%

Operating Profit Margin (Excl OI)

-17,294.30%

-24,264.30%

697.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2022 is 36.84% vs 11.76% in Dec 2021

Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 1.99% vs -11.85% in Dec 2021

All Annual Results

Company CV

About Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Company Coordinates

Company Details

1100 Massachusetts Ave Ste 4 , CAMBRIDGE MA : 02138-5241

Tel: 1 617 4531000

http://www.infi.com

Registrar Details

Infinity Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

Who are in the management team of Infinity Pharmaceuticals, Inc.?

Watch in Real-Time

Is Infinity Pharmaceuticals, Inc. overvalued or undervalued?

Is Infinity Pharmaceuticals, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'23 - QoQ

Annual Results Snapshot (Consolidated) - Dec'22

About Infinity Pharmaceuticals, Inc.

Company Coordinates